
This study aimed to assess the safety and efficacy of tirzepatide in people of East Asian descent based on age and body mass index (BMI). At baseline, 73% of East Asian participants had a BMI of 25 kg/m2, or more significant, and 74% were younger than 65 . At week 52, tirzepatide induced a similar dose‐dependent reduction in HbA1c, waist circumference and BMI across subgroups. Across all BMI and age subgroups, mean absolute HbA1c decreases across the three doses ranged from 2.3% to 3.0%, and mean waist circumference reductions ranged from 4.3 to 9.8 cm. This post hoc analysis showed that once‐weekly tirzepatide had a similar safety and efficacy profile across BMI and age subgroups in East Asian participants.
Like
Save
Share